A single drug could attack the virus on two fronts
Gladstone welcomes inquiries from journalists. Our media-relations staff is on hand to provide local, regional, national, and international journalists with accurate information about Gladstone’s research and our investigators’ areas of expertise. We are available to arrange interviews with Gladstone scientists and assist in developing story ideas.
Julie Langelier, Science Writer and Public Relations Specialist
Direct line: 415.734.5000
Megan McDevitt, Vice President of Communications
Direct line: 415.734.2019
The discovery could improve treatments for autoimmune diseases and cancer
Studer was selected for his groundbreaking research in stem cell–based therapies for Parkinson’s disease
E-Scape Bio, a Gladstone spin-off company, extends its Series A financing to generate novel therapies to treat neurodegenerative disorders
Researchers show that semen amyloids help the human body dispose of excess and defective sperm
Cells associated with seizures, schizophrenia, and ADHD found in the same region of the brain.
SAN FRANCISCO, CA—After decades of research aiming to understand how DNA is organized in human cells, scientists at the Gladstone Institutes have shed new light on this mysterious field by discovering how a key protein helps control gene organization.
SAN FRANCISCO, CA—A team of researchers at the Gladstone Institutes uncovered a new strategy to treat heart failure, a leading contributor to mortality and healthcare costs in the United States.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes discovered that an enzyme called SMYD2 could be a new therapeutic target for flushing out the HIV that hides in infected individuals. Overcoming this latent virus remains the most significant obstacle to a cure.
SAN FRANCISCO, CA—Scientists from the Gladstone Institutes identified that mutations in a protein commonly linked to frontotemporal dementia (FTD) result in obsessive-like behaviors.